re-clinical trials and possibly early phase
("first in man") clinical trials. If therapeutic drug candidates reach this
early stage of development, Champions Biotechnology intends to sell,
partner with, or license them to pharmaceutical and/or biotechnology
companies, as appropriate. Management believes this strategy will enable
Champions Biotechnology to leverage the competencies of these partners or
licensees to maximize Champions Biotechnology's return on investment in a
relatively short time frame. Champions Biotechnology believes that this
model is unlike that of typical new biotechnology companies that look to
bring the process of drug development through all phases of discovery,
development, regulatory approvals, and marketing, which requires a very
large financial commitment and a long time, typically more than a decade,
to realize.
In February 2007, Champions Biotechnology acquired the patent rights to
two Benzoylphenylurea (BPU) sulfur analog compounds that have shown
promising potent activity against prostate and pancreatic cancer cell
lines.
In May 2007, Champions Biotechnology acquired Biomerk Inc. a company
focused on generating a novel preclinical platform of human cancer tumor
immune-deficient mice xenografts (Biomerk Tumorgrafts(TM)). Biomerk
Tumorgrafts(TM), unlike standard cell line derived xenografts, are
implanted directly from primary human cancer tumors and never passaged in
cell tissue culture. Champions Biotechnology believes that these xenografts
more closely reflect human cancer biology and are more predictive of
clinical outcome. Champions Biotechnology believes that it as well as
biotechnology and pharmaceutical companies, as part of their drug discovery
and post marketing efforts, may benefit from utilizing services that are
more predictive and that might provide for a faster and less expensive path
for drug approval. These services will utilize Biomerk Tumorgrafts(TM) to
evaluate tumor sensitivity/resistance to various sing
'/>"/>
SOURCE Champions Biotechnology, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related biology technology :1.
Germantown drug company hires pharma veteran James Davidson as COO2.
David Brooks: Segmented nation looks for solidarity amid IT-powered niches3.
CIO Leadership Series: Rick Davidson, Manpower4.
CIO Leadership Series: David Melbye, Milwaukee Metro Sewerage District5.
CIO Leadership Series: David Cagigal, Alliant Energy6.
VanderSanden appointed president of AT&T Wisconsin7.
Kyron appoints former AMA chairman to board8.
Third Wave appoints new chairman9.
Cisco Chairman donates $31 million for UW building renovation10.
Bone Care Names New Chairman11.
Cisco Chairman Praises University Research